Trial Profile
ZOmeta-Femara Adjuvant Synergy Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary) ; Letrozole
- Indications Early breast cancer; Osteoporosis
- Focus Therapeutic Use
- Acronyms ZO-FAST
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium.
- 02 Dec 2011 Five-year follow-up data on long-term overall survival outcomes will be presented at the 34th Annual San Antonio Breast Cancer Symposium, according to a Novartis media release.
- 24 May 2010 New trial record